Article citationsMore>>

Mavoko, H.M., Nabasumba, C., da Luz, R.I., Tinto, H., D’Alessandro, U., Kambugu, A., et al. (2017) Efficacy and Safety of Re-Treatment with the Same Artemisinin-Based Combination Treatment (ACT) Compared with an Alternative ACT and Quinine plus Clindamycin after Failure of First-Line Recommended ACT (QUINACT): A Bicentre, Open-Label, Phase 3, Randomised Controlled Trial. The Lancet Global Health, 5, e60-e68. https://doi.org/10.1016/S2214-109X(16)30236-4 https://www.sciencedirect.com/science/article/pii/S2214109X16302364

has been cited by the following article:

• TITLE: Critical Analysis of the Literature Comparing Artemisinin-Based Combination Therapy and Quinine Treatments for Uncomplicated Malaria in Pregnancy

  AUTHORS: Damien Mbanzulu Pita Nsonizau, Daniel Kiozi Kouzitissa, Nekwei Wasadidi, Tacite Kpanya Mazoba, Mamanisini Kiaku-Mbuta Damien

  KEYWORDS: Artemisinin, Quinine, Comparison, Efficacy, Malaria, Pregnancy

  JOURNAL NAME: Open Access Library Journal, Vol.11 No.1, January 12, 2024

  ABSTRACT: In areas of high P. falciparum resistance, artemisinin derivatives and quinine are recommended as effective antimalarial drugs. In four randomized clinical trials, artemisinin- and quinine-based treatments (Quinine versus Artesunate-Atovaquone-Preguanil; Quinine versus Artesunate-Mefloquine; Quinine-Clindamycin versus Artesunate, Quinine versus Artemether-Lumefantrine) were compared to determine which regimen was more effective in treating uncomplicated malaria in pregnant women. It was not possible to make this choice as artemisinin derivatives in combination were compared with quinine alone and vice versa, as the WHO recommends dual therapy for the treatment of uncomplicated malaria in pregnant women. All regimens have been shown to be effective, with good tolerability and compliance, and less side-effects for artemisinin derivatives, and poor compliance and observance, as well as greater side-effects, for quinine. Balanced comparative studies will be useful in the future to settle this question.